Discovery & Innovation

This is the third and final post of a series (part 1 and part 2) on directed evolution. What do protein engineers actually produce using directed...

Three outstanding examples for fragment-based drug discovery A good example for the reliability of the fragment-based screening method is the...

Directed evolution is emerging as a powerful new tool to design proteins with new and interesting properties that may not have evolved naturally...

Illumina recently announced the $1000 solution for the sequencing of the human genome in the form of its new instrument, the HiSeqX. This system...

The selection and accumulation of desirable mutations – also known as natural selection – has shaped the living world. The proteins resulting from...

One major challenge in drug discovery is determining whether a drug is behaving as intended, binding the “right” protein, inhibiting the correct...

This is Part 3 in a three-part series on Big Data in the pharma and biotech industries. (Check out Part 1 and Part 2). Big Data — the vast amount...

This is Part 2 in a three-part series on Big Data in the pharma and biotech industries. (Check out Part 1 and Part 3). Recent medical technology...

This is Part 1 in a three-part series on Big Data in the pharma and biotech industries. (Check out Part 2 and Part 3). Medical research and...

The need for CNS therapeutics is on the rise. Neurological diseases are expected to increase steadily in the coming years. Previously, we addressed...